Low Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa "SPRINT"

Not yet recruiting

Phase 3 Results N/A

Summary of Purpose

The overall goal of the proposed study is to determine the effectiveness of hydroxyurea therapy for secondary stroke prevention and prevention of other neurological events in children with SCA with an acute overt stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 4 February 2016.

1 Jul 2016 8 Jan 2016 1 Jul 2019 1 Dec 2019 1 Feb 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Prevention
  • Endpoint: Safety/Efficacy Study
  • Intervention: Single Group Assignment

Contacts